demonstrated that the DNA methylation profile of an LGALS3 promoter was unmethylated in nonmucinous colorectal carcinomas, whereas LGALS3 was aberrantly methylated in mucinous colorectal carcinomas.
Despite being a protein with well-defined functions in blood and tissue, no study has yet explored LGALS3 (galectin-3) gene variations and mutations in colorectal cancers.
Afterwards, polymerase chain reaction (PCR) restriction fragment length polymorphism (RFLP) methods were utilized to genotype rs4644 and rs4652 variants of the LGALS3 gene.
The distribution of the genotypes pertaining to the rs214250 variant of the AXIN1 gene, the rs4644 variant of the LGALS3 gene, and the rs4652 variant of the LGALS3 gene were shown in Table 3.
Genotypes of the rs4644 variant of the LGALS3 gene had a significantly different distribution between patient and control groups (p=0.
The AACC haplotype of the rs4652 variant of the LGALS3 gene and the rs214250 variant of the AXIN1 gene had a significantly lower frequency in the patient group compared to the control group (3.
The CCCT haplotype of the rs4644 variant of the LGALS3 gene and the rs214250 variant of the AXIN1 gene had a significantly higher frequency in the patient group compared to the control group (18.
In triple haplotyping of the rs4652 and rs4644 variants of the LGALS3 gene and the rs214250 variant of the AXIN1, the CCAACT haplotype was significantly more common in the patient group than in the control group (12.
Previous studies have shown that LGALS3 plays a role in the Wnt/[beta]-catenin pathway and is involved in cell migration and invasion, with its levels proportional to [beta]-catenin in different cancer types [29,30].
Experimental animal models have similarly shown increased LGALS3 m-RNA levels in colorectal tissue .
Genetic studies investigating the mucinous component are quite limited and the LGALS3 rs4644 variant CC genotype was correlated to a mucinous component in our study.